Formica Francesco, Avalli Leonello, Colagrande Luisa, Ferro Orazio, Greco Gianluca, Maggioni Elena, Paolini Giovanni
Cardiac Surgery Clinic, Department of Surgical Science, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy.
Interact Cardiovasc Thorac Surg. 2010 May;10(5):721-6. doi: 10.1510/icvts.2009.220335. Epub 2010 Feb 1.
Adult patients supported on extracorporeal membrane oxygenation (ECMO) are very sick and many complications are often present in each single patient; therefore, it is not always easy to find some risk factors that can predict the early outcome. This retrospective study reports our experience in ECMO support treatment in adult cardiac patients suffering from cardiac failure (CF) in which one or more predictive factors of 30-day mortality were analyzed. Between January 2002 and August 2009, 42 consecutive adult cardiac patients with cardiogenic shock (mean age 64.3+/-11.3 years) were supported on ECMO for >2 days. They were divided into patients who had a survival <30 days (n=20) and patients who survived >30 days (n=22). Twenty-nine patients (69%) survived on ECMO. Sixteen patients were discharged with a survival rate of 38.1%. The overall mean ECMO duration was 7.9+/-5.3 days. The following variables were significantly different between the two groups: number of platelets and packed red blood cells (PRBCs) transfused per day during ECMO (P=0.002 and P=0.003), blood lactate levels 48 h and 72 h after the initiation of ECMO (P=0.01 and P=0.04), indexed blood flow after 48 h and 72 h (P=0.01 and P<0.0001), liver failure (P=0.001) and multiorgan failure (P=0.002). Stepwise logistic regression identified that blood lactate levels at 48 h and number of PRBCs transfused were associated with 30-day mortality [P=0.019, odds ratio (OR) =2.16; 95% confidence interval (CI)=1.13-4.14 and P=0.008, OR=1.08; 95% CI=1.02-1.14, respectively]. The predicted probability of mortality would be 52% when blood lactate levels are >3 mmol/l after 48 h. The blood lactate level at 48 h and PRBCs transfused per day can be considered as important parameters to predict the mortality in adult cardiac patients supported by ECMO for CF.
接受体外膜肺氧合(ECMO)支持的成年患者病情非常严重,每位患者通常都存在多种并发症;因此,要找到一些能够预测早期预后的危险因素并非总是易事。这项回顾性研究报告了我们对成年心力衰竭(CF)心脏患者进行ECMO支持治疗的经验,其中分析了30天死亡率的一个或多个预测因素。在2002年1月至2009年8月期间,42例连续性成年心源性休克心脏患者(平均年龄64.3±11.3岁)接受ECMO支持超过2天。他们被分为存活时间<30天的患者(n = 20)和存活时间>30天的患者(n = 22)。29例患者(69%)在ECMO支持下存活。16例患者出院,存活率为38.1%。ECMO的总体平均持续时间为7.9±5.3天。两组之间以下变量存在显著差异:ECMO期间每天输注的血小板数量和红细胞压积(PRBCs)(P = 0.002和P = 0.003)、ECMO开始后48小时和72小时的血乳酸水平(P = 0.01和P = 0.04)、48小时和72小时后的指数血流量(P = 0.01和P<0.0001)、肝功能衰竭(P = 0.001)和多器官功能衰竭(P = 0.002)。逐步逻辑回归分析确定,48小时时的血乳酸水平和输注的PRBCs数量与30天死亡率相关[P = 0.019,比值比(OR)=2.16;95%置信区间(CI)=1.13 - 4.14和P = 0.008,OR = 1.08;95%CI = 1.02 - 1.14]。当48小时后血乳酸水平>3 mmol/L时,预测死亡率为52%。48小时时的血乳酸水平和每天输注的PRBCs可被视为预测CF成年心脏患者接受ECMO支持时死亡率的重要参数。